Evidence map›Paper›PMID 27630569›Full record

ArticleFrontiers in pharmacology2016

Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia.

Oxana Dobrovinskaya, Georgina Valencia-Cruz, Luis Castro-Sánchez, Edgar O Bonales-Alatorre, Liliana Liñan-Rico, Igor Pottosin

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Heart-Rate Variability-More than Heart Beats?Frontiers in public health · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Oxana DobrovinskayaCentro Universitario de Investigaciones Biomédicas, Universidad de Colima Colima, México.
Georgina Valencia-CruzCentro Universitario de Investigaciones Biomédicas, Universidad de Colima Colima, México.
Luis Castro-SánchezCentro Universitario de Investigaciones Biomédicas, Universidad de ColimaColima, México; Consejo Nacional de Ciencia y TecnologíaMéxico City, México.
Edgar O Bonales-AlatorreCentro Universitario de Investigaciones Biomédicas, Universidad de Colima Colima, México.
Liliana Liñan-RicoCentro Universitario de Investigaciones Biomédicas, Universidad de Colima Colima, México.
Igor PottosinCentro Universitario de Investigaciones Biomédicas, Universidad de Colima Colima, México.
Universidad de Colima · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various types of non-neuronal cells, including tumors, are able to produce acetylcholine (ACh), which acts as an autocrine/paracrine growth factor. T lymphocytes represent a key component of the non-neuronal cholinergic system. T cells-derived ACh is involved in a stimulation of their activation and proliferation, and acts as a regulator of immune response. The aim of the present work was to summarize the data about components of cholinergic machinery in T lymphocytes, with an emphasis on the comparison of healthy and leukemic T cells. Cell lines derived from acute lymphoblastic leukemias of T lineage (T-ALL) were found to produce a considerably higher amount of ACh than healthy T lymphocytes. Additionally, ACh produced by T-ALL is not efficiently hydrolyzed, because acetylcholinesterase (AChE) activity is drastically decreased in these cells. Up-regulation of muscarinic ACh receptors was also demonstrated at expression and functional level, whereas nicotinic ACh receptors seem to play a less important role and not form functional channels in cells derived from T-ALL. We hypothesized that ACh over-produced in T-ALL may act as an autocrine growth factor and play an important role in leukemic clonal expansion through shaping of intracellular Ca(2+) signals. We suggest that cholinergic machinery may be attractive targets for new drugs against T-ALL. Specifically, testing of high affinity antagonists of muscarinic ACh receptors as well as antagomiRs, which interfere with miRNAs involved in the suppression of AChE expression, may be the first choice options.

Indexed as

acetylcholineacetylcholinesterasecalcium signalingcholine acetyltransferasemuscarinic receptor non-neuronal cholinergic systemT leukemiaT lymphocyte

Identifiers

PMID27630569
PMCPMC5005329
OpenAlexW2510448083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.